Catalyst Pharmaceuticals, Inc. 是一家处于商业化阶段、以患者为中心的生物制药公司,专注于授权引进、开发和商业化用于治疗罕见且难治疾病的创新药物。公司总部位于佛罗里达州珊瑚阁市,目前有181名全职员工。该公司于2006年11月8日上市。公司目前销售三种药品:FIRDAPSE(amifampridine)、FYCOMPA(perampanel)和AGAMREE(vamorolone)。FIRDAPSE用于治疗6岁及以上年龄的Lambert-Eaton重症肌无力综合征(LEMS)患者。通过其分许可授权方,该公司还在加拿大和日本提供FIRDAPSE。FYCOMPA是一种处方药物,可单独或与其他药物联合用于治疗患有癫痫且伴有或不伴有继发性全面性癫痫发作的4岁及以上患者的部分发作性癫痫,以及与其他药物联合治疗12岁及以上患者的原发性全面性强直-阵挛性癫痫发作。AGAMREE是一种皮质类固醇,其结构保留了传统皮质类固醇在杜氏肌营养不良症中使用的强效抗炎作用。
CPRX stock price ended at $0 on 星期二, after dropping NaN%
On the latest trading day Aug 11, 2026, the stock price of CPRX fell by NaN%, dropping from $NaN to $NaN. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $NaN and a high of $NaN. On the latest trading day, the trading volume for CPRX decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, -- shares were traded, with a market value of approximately --.